ANAVEX®2-73 (blarcamesine) tauted as a cure for Rett syndrome.
Mutations in methyl CpG binding protein 2 (MeCP2) are the major cause of Rett syndrome (RTT), a rare neurodevelopmental disorder with a notable period of developmental regression following apparently normal initial development. Such MeCP2 alterations often result in changes to DNA binding and chromatin clustering ability, and in the stability of this protein. Among other functions, MeCP2 binds to methylated genomic DNA, which represents an important epigenetic mark with broad physiological implications, including neuronal development.
ANAVEX®2-73 (blarcamesine) will not correct the mutations in methyl CpG binding protein 2 (MeCP2) gene.
ANAVEX®2-73 (blarcamesine) can and apparently does positively affect the causes of some or the symptoms of Rett syndrome.
Good luck and GOD bless,
Market Data 
Markets 
AI
